FDA Advisory Committee votes in favour of the clinical benefit of Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma March 9, 2023March 10, 2023 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: FDA accepts supplemental Biologics License…CHMP recommends EU approval of Roche’s Polivy…Roche’s Polivy combination approved by European…Roche presents new and updated data for Polivy in…Roche’s Polivy combination reduced the risk of…FDA grants priority review to Roche’s bispecific…
